In digestive pathologies—where PYK2-H drives cancer metastasis (HCC/PDAC) and inflammation (IBD)—PYK2-M may similarly antagonize these processes through kinase-independent scaffolding, though direct evidence remains limited and warrants investigation. Here, PTK2B is linked to hepatocellular carcinoma.